Literature DB >> 10867196

Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death.

A K Ghosh1, M Majumder, R Steele, K Meyer, R Ray, R B Ray.   

Abstract

Hepatitis C virus (HCV) often causes a prolonged and persistent infection which may lead to hepatocellular carcinoma. We have previously reported that the nonstructural 5A (NS5A) protein of HCV promotes cell growth [Ghosh, A.K., Steele, R., Meyer, K., Ray, R., Ray, R.B., 1999. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J. Gen. Virol. 80, 1179-1183]. In this study, we investigated the role of HCV NS5A (genotype 1a, strain H) in TNF-alpha induced apoptotic cell death. HepG2 cells expressing NS5A exhibited an inhibitory role in relation to TNF-alpha mediated apoptotic cell death. The NS5A protein blocked the activation of caspase-3 and inhibited proteolytic cleavage of the death substrate poly (ADP-ribose) polymerase in TNF-alpha induced cells. Together, these results suggest that HCV NS5A protein protects against TNF-alpha mediated apoptotic cell death.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867196     DOI: 10.1016/s0168-1702(00)00141-6

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  23 in total

Review 1.  The role of cirrhosis in the etiology of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  J Gastrointest Cancer       Date:  2014-03

2.  Tumor-initiating stem-like cells and drug resistance: carcinogenesis through Toll-like receptors, environmental factors, and virus.

Authors:  Keigo Machida
Journal:  Drug Deliv Transl Res       Date:  2013-04       Impact factor: 4.617

3.  Specific ssDNA concentration in liver tissue as an index of apoptosis in hepatitis C virus-infected patients.

Authors:  Tadeusz-Wojciech Lapinski; Anatol Panasiuk; Jerzy Jaroszewicz; Oksana Kowalczuk; Robert Flisiak; Magdalena Rogalska
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

Review 4.  Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.

Authors:  Yujin Hoshida; Bryan C Fuchs; Nabeel Bardeesy; Thomas F Baumert; Raymond T Chung
Journal:  J Hepatol       Date:  2014-11-03       Impact factor: 25.083

Review 5.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

6.  Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients.

Authors:  Tadeusz-Wojciech Lapinski; Oksana Kowalczuk; Danuta Prokopowicz; Lech Chyczewski
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

Review 7.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

8.  Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription.

Authors:  Andrew Street; Andrew Macdonald; Christopher McCormick; Mark Harris
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

10.  Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.

Authors:  Yupeng He; Haruhisa Nakao; Seng-Lai Tan; Stephen J Polyak; Petra Neddermann; Sangeetha Vijaysri; Bertram L Jacobs; Michael G Katze
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.